Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 06, 2026
Tencent Music Entertainment Group (TME) Stock: Can It Reach $12.50 (+59% Upside)?

Tencent Music Entertainment Group (TME) Stock: Can It Reach $12.50 (+59% Upside)?

Key Takeaways

  • The central target used here is $12.50, the arithmetic mean of seven current, individually attributable analyst price targets, rounded to a clean level.
  • With TME trading near $7.87, reaching $12.50 implies roughly 59% upside — a very large move.
  • The seven verified targets span roughly $8.44 to $20.00, an unusually wide range that signals real disagreement.
  • Sentiment has cooled sharply: multiple firms downgraded TME to Hold or Neutral during 2026 after slowing subscription growth and softer margin guidance.
  • Key supports include a cheap valuation, active buybacks, and long-term monetization of SVIP tiers and Ximalaya.
  • The biggest risks are competition from ByteDance's Soda music app, structural margin pressure, and execution risk around newer initiatives.

Breaking Down the Analyst Price Targets

The $12.50 central target is not an official published consensus. It is the arithmetic mean of seven current, individually identifiable targets I reviewed, each tied to a named firm and date: J.P. Morgan at $9.00 (Hold), Nomura at $10.00, China Renaissance at $9.30 (downgraded to Hold), UBS at $15.00 (Hold), Mizuho at $15.00 (Buy), 86Research at $20.00 (Buy), and BCS Global Markets at $8.44 (Neutral). The mean of these is about $12.39, rounded to $12.50. The range — roughly $8.44 to $20 — is exceptionally wide.

Bullish firms such as Mizuho and 86Research frame recent weakness in core music and non-subscriber segments as temporary, arguing the broader ecosystem and longer-term execution remain intact. Cautious firms such as J.P. Morgan, China Renaissance and BCS point to slower paid-user conversion, competitive pressure from Soda, and structurally lower 2026 gross and net margins as the mix shifts toward lower-margin concerts, merchandise and IP. Notably, Morgan Stanley, Benchmark and Daiwa each downgraded TME to Hold or Equal Weight earlier in 2026, while Barclays has stayed constructive. Some data providers still show higher average targets, but several of those reflect pre-decline figures that were set before the stock's collapse and the latest guidance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where TME Stands Today and the Road Ahead

At a latest verified price near $7.87, a move to $12.50 requires roughly 59% appreciation — a very large advance by any standard. That upside reflects how far expectations have already fallen: forward multiples have compressed to roughly 8x price-to-earnings (P/E) and around 4.7x enterprise value-to-EBITDA (earnings before interest, taxes, depreciation and amortization), according to recent broker commentary.

The path would likely require the market to regain confidence that the core music business has stabilized. Second-quarter 2026 revenue grew only about 5.8% year over year, with adjusted profit per ADR up about 2.4%; excluding the acquired Ximalaya, organic growth was closer to 1%. Management has guided to structurally lower margins for 2026, and the ADRs fell roughly 12% after the report. Reaching $12.50 would therefore depend less on valuation alone and more on evidence that subscription growth, average revenue per user, and margin trends are bottoming. From what I see, this makes the next few quarters particularly important to monitor.

Factors That Could Help Reach the Target

  • Valuation reset. At single-digit forward earnings, TME is inexpensive versus its own history, which some analysts see as pricing in too much pessimism.
  • Capital returns. The company repurchased about $400 million of shares in the second quarter of 2026, roughly 2.8% of shares outstanding, supporting per-share metrics.
  • Monetization levers. Higher-priced SVIP subscriptions, artist fan offerings, and ticket-linked perks give engaged users reasons to keep paying.
  • Ximalaya and Weixin integration. Cross-selling long-form audio and music discovery through Tencent's Weixin ecosystem could widen the paying base without proportional ad spending.

Risks That Might Hold It Back

  • Competition from Soda. ByteDance's Soda music app, fed by Douyin short-video discovery, pressures TME's ability to add subscribers or raise prices, potentially forcing discounts and higher retention costs.
  • Margin compression. A continued shift toward lower-margin concerts and merchandise may keep earnings growth muted even if revenue recovers.
  • Execution risk. Monetizing Ximalaya and new IP services may fall short of expectations, weighing on earnings.
  • Structural headwinds. AI-generated music and piracy are emerging threats to paid subscriptions and advertising yields, and the NYSE-listed ADR is being dropped from the FTSE All-World Index, a modest technical overhang.

Technical Levels to Watch

TME trades just above its 52-week low near $7.66, an important support level. A sustained break below that level would signal continued downside, while recovery faces layered resistance: the $9–$10 zone, where several cautious targets cluster, then $12–$13, and finally the $15 area held by UBS and Mizuho. The stock's long-term trend remains firmly lower after the 2025–2026 drawdown, so any move toward $12.50 would first require reclaiming and holding the $10 area. I’m watching this closely for any signs of stabilization.

What to Keep an Eye On Going Forward

Analyst price targets generally reflect a research horizon of about 12 months, though firms rarely state an identical timeframe, and individual targets can reflect different assumptions. Investors should watch upcoming quarterly results for evidence that paid-subscriber growth and margins are stabilizing, any update on Soda's competitive impact, progress on Ximalaya cross-selling and the Weixin integration, and further analyst revisions — which have been decisively lower in 2026. Broader China consumer data and any changes to buyback activity also matter for the outlook. One thing that stands out is how quickly sentiment shifted in 2026.

Leveraging AI Tools in My Research

When reviewing names like TME, I find Tickeron's AI Daily Buy/Sell Signals useful for spotting momentum shifts. The platform applies artificial intelligence across thousands of stocks to generate signals based on technical and market conditions. It offers a practical way to stay informed without replacing deeper fundamental work.

Final Assessment

Can Tencent Music Entertainment Group stock reach $12.50? The target — the arithmetic mean of seven current analyst price targets spanning roughly $8.44 to $20 — sits about 59% above the latest price, a very large move that would require a decisive reversal of the slowdown in subscriptions and margins. The supportive case rests on a deeply reset valuation, active buybacks, and long-term monetization of SVIP and Ximalaya. The opposing case rests on Soda's competitive pressure, structurally lower margins, and execution risk. The unusually wide target range shows analysts themselves are split on whether the core business has bottomed. What happens to subscriber growth and margin guidance in the next few quarters will likely determine whether a move toward $12.50 is realistic. No outcome is guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TME

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TME sees MACD Histogram crosses below signal line

TME saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 35 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TME as a result. In 69 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for TME entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TME's RSI Oscillator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +2.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where TME advanced for three days, in 205 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

TME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.170) is normal, around the industry mean (1.315). P/E Ratio (9.824) is within average values for comparable stocks, (405.942). Projected Growth (PEG Ratio) (2.018) is also within normal values, averaging (17.274). Dividend Yield (0.029) settles around the average of (0.015) among similar stocks. P/S Ratio (2.417) is also within normal values, averaging (70.877).

The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Alphabet (NASDAQ:GOOG), Alphabet (NASDAQ:GOOGL), Meta Platforms (NASDAQ:META), Spotify Technology SA (NYSE:SPOT), Nebius Group N.V. (NASDAQ:NBIS), Baidu (NASDAQ:BIDU), Tencent Music Entertainment Group (NYSE:TME), Pinterest (NYSE:PINS), Snap (NYSE:SNAP), Bilibili (NASDAQ:BILI).

Industry description

Companies in this industry typically license software on a subscription basis and it is centrally hosted. Such products usually go by the names web-based software, on-demand software and hosted software. Cloud computing has emerged as a major force in this space, making it possible to save files to a remote database (without requiring them to be saved on local storage device); as long as a device has access to the web, it can access the data and the software programs to run it. This has in many cases facilitated cost efficiency, speed and security of data for businesses and consumers. Alphabet Inc., Facebook, Inc. and Yahoo! Inc. are some well-known names in the internet software/services industry.

Market Cap

The average market capitalization across the Internet Software/Services Industry is 148.16B. The market cap for tickers in the group ranges from 107 to 4.19T. GOOG holds the highest valuation in this group at 4.19T. The lowest valued company is STBXF at 107.

High and low price notable news

The average weekly price growth across all stocks in the Internet Software/Services Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -6%. SJ experienced the highest price growth at 31%, while CCG experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the Internet Software/Services Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 30% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 73
Price Growth Rating: 65
SMR Rating: 77
Profit Risk Rating: 94
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
TME
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an online music entertainment platform

Industry InternetSoftwareServices

Industry
Internet Software Or Services
Address
Kexing Science Park, Kejizhongsan Avenue
Phone
+86 75586013388
Employees
5690
Web
https://www.tencentmusic.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.